Sanofi Commits $20 Bn to U.S. R&D and Manufacturing Through 2030

In 2024, the company reported global net sales of 41.8 billion euros ($45.2 billion), with nearly half—20 billion euros ($21.6 billion)—coming from the U.S. market.

Sanofi announced a $20 billion investment plan to expand its research, development, and manufacturing operations in the United States by 2030.

The Paris-based pharmaceutical company plans to increase manufacturing capacity at its current U.S. sites and strengthen partnerships with domestic manufacturers to ensure medicine production within the country.

Sanofi highlighted that the investment will generate numerous high-paying jobs across multiple states.

“Sanofi's 13,000 U.S.-based employees are pioneering the research and development of first- and best-in-class medicines across numerous therapeutic areas,” said Sanofi CEO Paul Hudson.

In 2024, the company reported global net sales of 41.8 billion euros ($45.2 billion), with nearly half—20 billion euros ($21.6 billion)—coming from the U.S. market.

Industry-Wide Investment Amid Pricing Policy Changes

Sanofi’s commitment adds to similar recent announcements by major pharmaceutical firms, including Eli Lilly, Johnson & Johnson, Gilead Sciences, and Novartis, which are increasing their U.S. investments in R&D and manufacturing. For instance, Novartis revealed a $23 billion investment plan for the U.S. over the coming years.

At the same time, Roche expressed concerns about the impact of President Donald Trump’s recent Executive Order aimed at reducing drug prices through a “Most Favored Nation” pricing scheme. The order, signed on Monday, has led Roche to reconsider its previously announced $50 billion U.S. investment plan over five years. A Roche spokesperson stated, “Should the proposed Executive Order go into effect, Roche’s ability to fund the significant investments previously announced in the U.S. will be in question.” The company also warned that the order “will undermine the U.S.’s position as the world’s leading pharmaceutical and healthcare ecosystem, dampen economic growth and lead to job losses in the U.S.”

In a press briefing before signing the order, President Trump acknowledged and praised pharma companies for their planned investments in the U.S., suggesting a possible shift away from earlier threats to impose tariffs on imported drugs.

Stay tuned for more such updates on Digital Health News